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In developing this special issue, we sought to raise awareness
of the potential of antimicrobial peptides (AMPs) for clinical
use and to highlight recent developments in the field. The
issue contains research articles covering the full spectrum
of contemporary work, ranging from the rational design of
synthetic peptides and discovery of bacteriocins, to testing of
the eﬃcacy of AMPs in animal models. We have included two
expert reviews reflecting on the potential of both eukaryotic
and prokaryotic peptide antibiotics for clinical use.
The antibiotic development pipeline is devoid of immi-
nent solutions to the problems caused by resistant gram-
negative bacteria and only a small number of new agents
exist for therapy of infections caused by gram-positives. The
pathway for development of new antibiotics is both long and
extremely expensive and, therefore, “big-pharma” has not
invested significantly in this area for decades.
The scarcity of antibiotics to combat infectious disease
is commonly acknowledged and the specter of untreat-
able infections has been widely publicized. However, some
additional potential impacts of the absence of eﬃcacious
antibiotics are not as widely discussed. The inability to reli-
ably treat infections could potentially mean that all elective
surgery ceases, and, moreover, there could be significant
restrictions placed on the use of cancer chemotherapy. Thus,
in order to maintain anything like the level of medical care
that many of us now enjoy, we must devote considerable
eﬀort to find solutions to this steadily-evolving clinical
dilemma. AMPs appear to merit a prominent position in
the catalogue of pharmaceuticals that should be more ex-
haustively investigated in our search for new antimicrobial
agents.
Many AMPs have potent activity against bacteria, includ-
ing those that are resistant to conventional antibiotics. Their
activity is often relatively-specifically directed against certain
genera or groups of bacteria, which could limit damaging
eﬀects on a patient’s commensal flora. AMPs generally
exhibit high stability to wide ranges in pH and temperature,
characteristics that may be beneficial for their scaled-up pro-
duction and formulation into deliverable products. Also, due
to their rather specific modes of action, many AMPs exhibit
low toxicity for eukaryotic cells, providing an opportunity for
a wide therapeutic window. Their typical mode of action is
also linked to a low propensity for resistance development
in target bacteria. These unique features diﬀerentiate AMPs
from many conventional antibiotics.
Outside of the potential use of AMPs as alternatives
to antibiotics with respect to the treatment/prevention of
disease, numerous recent reports have also described the
activity of AMPs against bacteria growing in biofilms, that is,
communities encased in structured matrices of extracellular
macromolecules, on medical devices. Medical devices can
become colonized with bacteria growing in biofilms, which
are resistant to elements of the host immune response and
to extremely high concentrations of conventional antibiotics.
Consequently, resolution of medical device-related infec-
tions usually requires the removal of the device. Notably,
low concentrations of some AMPs have been shown to have
inhibitory and disruptive properties that can eliminate even
well-established biofilms.
It is also important to consider the fact that some AMPs
have been shown to exhibit immunomodulatory properties;
that is, they can reduce the tissue-damaging inflamma-
tory response to infection, whilst stimulating antimicrobial
immune activities. Peptides exhibiting modulatory features,
as well as overt antimicrobial activity, are now being selected
as favoured candidates for further evaluation in clinical trials.
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Recently, the search for AMPs has benefited from a
number of advances in informatics and peptide engineer-
ing strategies. This, coupled with renewed interest from
big-pharma, manifested by some recent acquisitions of
companies using natural product screening approaches, is
increasing the prominence of AMPs. This current special
issue includes research articles and reviews that together
describe the process of discovery of AMPs, their testing in
in vivo models and outlines steps taken in the development
of clinically-relevant agents.
The paper by H. Jin-Jiang and colleagues describes the
design and synthesis of a range of AMPs and reports on
the activity of K11, a 20mer highly cationic helical pep-
tide with activity against gram-positive and gram-negative
bacteria, including drug resistant clinical isolates. K11 has a
high therapeutic index/window and clearly warrants further
investigation. Thus, the paper demonstrates the utility of
synthetic approaches to the development of novel chimeric
AMPs.
Also included in the special issue is a report by P. A.
Wescombe and colleagues, which focuses on the character-
ization of a bacteriocin from the SA-FF22 family produced
by members of the Streptococcaceae. The plasmid-encoded
peptide G32 was purified from a culture of Streptococcus
salivarius, a species known to include numerous bacteriocin
producers, and is active against the pathogen Streptococcus
pyogenes. An interesting feature of this lantibiotic peptide
is the apparent absence of an auto-induction capability.
The work supports previous suggestions that Streptococcus
salivarius mega-plasmids are repositories for lantibiotic loci
and that bacteria producing these lantibiotics can be eﬀective
probiotics.
C. Piper and colleagues demonstrate the utility of whole
animal bioimaging approaches to demonstrate that the
lactococcal lantibiotic lacticin 3147 could prevent systemic
spread of Staphylococcus aureus following subcutaneous
delivery of the peptide. This is important work as it adds
to the growing evidence base that suggests that lantibiotics
and other AMPs could potentially be used to control systemic
infections, most previous approaches having been restricted
to topical applications.
The two reviews included in this issue elegantly pre´cis
recent advances that have been made with AMPs derived
from both bacteria and insects. M. Ntwasa and colleagues
describe the medical potential of immune system peptides of
the coleopteran insects. The authors report that these ancient
eukaryotes have a highly developed and robust immune
system that has contributed to their survival. Exploitation
of the immune eﬀectors from these organisms holds great
potential for use in clinical medicine. The review also
describes the utility of databases and full genome sequence
determination in AMP discovery.
The paper by C. T. Lohans and J. C. Vederas is an exten-
sive review of the potential utility of the unmodified, or class
IIa, bacteriocins. The paper describes peptide engineering
approaches for increasing the value of bacteriocins, methods
for improved in vitro production and eﬃcient purification,
various in vivo delivery options and, finally, gives some atten-
tion to the important issue of the development of resistance
to bacteriocins. The paper concludes with a positive outlook
for the use of bacteriocins in medical therapy.
We agree that there is great potential for the use of AMPs
in clinical therapy for infectious disease, either through
direct antimicrobial activity or modulation of the immune
response to infection. Contributors to this special issue also
discuss the possibility for use of some AMPs in antitumor
therapy. AMPs oﬀer some significant advantages over con-
ventional antibiotics and we are now making important
advances in the discovery, optimization, and activity testing
of these agents. In parallel, publications in this field are
attracting the attention of increasing numbers of academic
and industrial researchers. It is genuinely an exciting time to
be involved in the development of AMPs and we trust that
this special issue leaves readers similarly enthused about the
subject.
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